Issue #11 | January 2023
Important Announcements
  • 50% enrollment goal met in December, ahead of schedule
  • Data Safety & Monitoring Board (DSMB) approved continuation of the feasibility study
Enrollment & Randomization Tracking
258
Patients Enrolled
204
Patients Randomized
Operational Updates
Protocol & Enrollment

  • Collecting lessons learned to share with full-scale sites
  • Feasibility protocol under review for publication at BMJ Open
  • Clinician Education Resources available on MPOG website
Information Systems

  • Developing automated operational metrics and reports
  • thrivetrial.org informational website
  • Continued refinement of data collection processes
Stakeholder Engagement
Timeline Update
The next major timepoints for the study include the end of feasibility and the beginning of full-scale.
Image credit Slidesgo and Freepik
Emerging & Relevant Literature
Ongoing trial comparing various anesthetic techniques on outcomes related to cancer
The Volatile Anaesthesia and Perioperative Outcomes Related to Cancer (VAPOR-C) trial is a large, international, randomized clinical trial of inhalational volatile or intravenous propofol anesthesia (TIVA) and intravenous lidocaine/placebo to improve disease free survival after surgery for colorectal cancer and lung cancer.

Our THRIVE trial was designed in part as a complement to VAPOR-C, in order to help contribute to the existing body of literature on TIVA.
Suggestion Box

Are our newsletters informative?
Could they be better?

Tell us how we're doing!

Funded by
Contract 2020C3-21106